Jefferies Raises CME Group (CME) Price Target on Strong Trading Volumes and Collateral Growth

CME Group Inc. (NASDAQ:CME) ranks among the best non-tech stocks to buy according to billionaires. Jefferies kept its Buy rating on CME Group Inc. (NASDAQ:CME) and increased its price target to $313 from $288 on July 14. Citing improved trading volumes across the majority of asset classes, the company raised its second-quarter 2025 earnings per share projection from $2.77 to $2.90.

Jefferies Raises CME Group (CME) Price Target on Strong Trading Volumes and Collateral Growth

While metals, energy, and interest rates were the main drivers of volume upside, Electronic Broking Services (EBS) and BrokerTech revenue forecasts of $73 million marginally surpassed the prior estimate of $70 million,.

Additionally, the firm reported that the average balances for cash collateral and non-cash collateral between March 1 and May 31 came in at $118.0 billion and $151.2 billion, respectively, following the implementation of a collateral fee increase by CME Group Inc. (NASDAQ:CME) on April 1.

The top derivatives marketplace in the world, CME Group Inc. (NASDAQ:CME), offers trading, clearing, and data services for a variety of key asset classes.

While we acknowledge the potential of CME to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CME and that has 100x upside potential, check out our report about this cheapest AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.